Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: HER2-positive Breast Cancer, Breast Cancer Metastatic
Interventions: Palbociclib 75mg, Letrozole 2.5mg, T-DM1, Palbociclib 100mg, Palbociclib 125mg, Palbociclib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Neoplasms
Interventions: pemetrexed, gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: CONSYDER decision aid; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Interventions: Palbociclib, Everolimus, Exemestane; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions: Tucatinib, Eribulin, Trastuzumab; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more

Conditions: Metastatic Breast Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Triple Negative Breast Cancer
Interventions: Not listed
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Breast Neoplasms
Interventions: Th2/Tc2 Cells; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Interventions: Ruxolitinib, Capecitabine, Regorafenib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more

Conditions: BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions: Mifepristone 200 MG, Prophylactic mastectomy; Drug · Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Breast Cancer
Interventions: omega 3 fatty acids; Dietary Supplement
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Duarte, California • Columbus, Ohio

Conditions: Breast Cancer
Interventions: Report symptoms via web or phone-based system; Other
Lead sponsor: BrightOutcome; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Tucson, Arizona • Seattle, Washington

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Conditions: Disease Progression
Interventions: De novo tumor tissue biopsy, Research blood draws; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more

Conditions: Breast Cancer
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC); Behavioral · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older · Female only
Enrollment: 668 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions: Apixaban alone, Cyclosporine, Tacrolimus, Apixaban; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Dual-Energy Contrast-Enhanced (DECE) mammography, digital mammography; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Neoplasms, Early Detection of Cancer
Interventions: Patient activation, Primary care physician activation, Control; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 25 Years and older · Female only
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: New York, New York • Durham, North Carolina • Memphis, Tennessee

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: oblimersen sodium, docetaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Carcinoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2100
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Optimizing Surgical Decisions in Young Adults With Breast Cancer

Palbociclib With Everolimus + Exemestane In BC

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Breast Cancer BRCA1 Carriers: a Pilot Study

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Treatment Resistance Following Anti-cancer Therapies

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Chemotherapy in Treating Patients With Solid Tumors

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer